Alpa Patel, MD
Ophthalmology · Los Angeles, CANPI 1528081098
Payments from drug & device makers
Across 144 payments — averaging $80.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$10K
- AbbVie$294
- Astellas Pharma US Inc$250
- Bausch & Lomb Americas Inc.$245
- Bausch & Lomb, A Division Of Bausch Health US, LLC$219
- Glaukos Corporation$166
- plus $884 from 21 others
What the payments were for
- Travel & lodging$300%
- Food & beverage$11,590100%
- Gifts$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 94 | $9,580 |
| AbbVie(2 entities) | 8 | $294 |
| Astellas Pharma US Inc | 2 | $250 |
| Bausch & Lomb Americas Inc. | 3 | $245 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $219 |
| Glaukos Corporation | 1 | $166 |
| Kala Pharmaceuticals, Inc. | 1 | $125 |
| Edwards Lifesciences | 1 | $120 |
| Ivantis, Inc | 2 | $96 |
| Amgen | 5 | $94 |
| Oyster Point Pharma, Inc. | 1 | $62 |
| Alcon Research LLC | 2 | $57 |
| Novartis | 2 | $44 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $30 |
| Genentech USA, Inc. | 1 | $29 |
| Sun Pharmaceutical Industries Inc. | 1 | $28 |
| Coherus Oncology, Inc. | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| Ocular Therapeutix, Inc. | 1 | $19 |
| Sight Sciences, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| GSK | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Revance Therapeutics, Inc. | 1 | $15 |
| Beaver-visitec International, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$3,711
- Hydrus Microstent$684
- AcrySof IQ PanOptix UV IOL$289
- Izervay$250
- AcrySof IQ VIVITY$243
- AcrySof IQ PanOptix$227
- iStent inject Trabecular Micro-Bypass Stent System$166
- Wavelight Refractive Suite$164
- Clareon PanOptix Pro$145
- AcrySof UltraSert$143
- ARGOS$141
- AcrySof IQ VIVITY IOL$139
- Precision7$126
- TRYPTYR$125
- AcrySof$125
- EYSUVIS$125
- MIEBO$124
- XIIDRA$124
- VUITY$123
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$120
How this compares
$11,637 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 63 | $33,137 |
| RhopressaNetarsudil Mesylate | 22 | $23,423 |
| RestasisCyclosporine | 12 | $14,171 |
| ProlensaBromfenac Sodium | 36 | $11,862 |
| Cyclosporine | 13 | $9,491 |
| Alphagan PBrimonidine Tartrate | 14 | $4,490 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $4,198 |
| Latanoprost | 262 | $4,054 |
| Prednisolone Acetate | 93 | $4,000 |
| Difluprednate | 47 | $3,800 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $3,027 |
| MoxifloxacinMoxifloxacin Hcl | 94 | $2,589 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 44 | $2,382 |
| Loteprednol Etabonate | 13 | $1,847 |
| Dorzolamide Hcl | 67 | $1,838 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $294 | $55,996103 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $219 | $13,70949 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Los Angeles
- Steven JacobsonLos Angeles$4.7M
- David BoyerLos Angeles$4M
- Firas RahhalLos Angeles$1.2M
- Nicole FramLos Angeles$1.2M
- Andrew MoshfeghiLos Angeles$1M
- Pradeep PrasadLos Angeles$901K
- Barry SeibelLos Angeles$835K
- David LiaoLos Angeles$722K
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.